HALO:NASDAQ
Halozyme Therapeutics, Inc.
$107.94
arrow_upward
+0.69%(+0.74) 1D
$107.29
arrow_downward
-0.60% (-0.65)bedtimeAfter hours
Closed: Sep 14, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$108.00
High
$108.61
Low
$106.65
Mkt. cap
12.25B
Avg. vol.
2.06M
Volume
0.00
P/E ratio
32.25
52-wk high
$111.15
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
Open
$108.00
High
$108.61
Low
$106.65
Mkt. cap
12.25B
Avg. vol.
2.06M
Volume
0.00
P/E ratio
32.25
52-wk high
$111.15
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
Zacks
·
11 hours ago
4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
Stock Titan
·
3 days ago
Halozyme (NASDAQ: HALO) CEO exercises options, sells 60,000 shares
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com